About: Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Sector: Healthcare
Industry: Biotechnology
Latest price: $135.07 (-0.01%)
APGENASDAQApogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. Common Stock share price
APGE price activity
Last Price
$135.070
Change (24hr)
-0.01 USD (-0.01%)
Volume
4.92M
Volume (4w avg)
-
Open
$135.06
Day Range
$135.06 - $135.09
Previous Close
$135.08
Last Trade
02 Sep, 8:05 pm GMT+0
Delayed
02 Sep, 8:05 pm GMT+0
APGE price performance
Delayed
02 Sep, 8:05 pm GMT+0
APGE Market Signals